{"entity":{"id":"pieter-sonneveld","kind":"person","name":"Pieter Sonneveld","aka":[],"tldr":"Led PERSEUS, which established daratumumab-VRd as the standard for transplant-eligible myeloma.","summary":"Pieter Sonneveld was principal investigator of PERSEUS, the trial showing daratumumab added to bortezomib-lenalidomide-dexamethasone before and after transplant improves progression-free survival and MRD negativity in newly diagnosed myeloma, and led the HOVON-65/GMMG-HD4 trial that established bortezomib in induction. He chairs the European Myeloma Network and has led HOVON myeloma trials for three decades.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sonneveld%20P%5BAuthor%5D%20myeloma%20daratumumab%20PERSEUS"}],"tags":["myeloma","transplant","hovon"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["monoclonal-antibody","mrd-testing"],"targets":["cd38"],"drugs":[],"companies":["hovon"],"institutions":["erasmus-mc"],"pathways":[],"terms":[],"trials":["perseus"],"people":[],"bottlenecks":[],"keyPapers":["paper-perseus-dara-vrd-transplant-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Hematology, Erasmus MC Cancer Institute; Chair, European Myeloma Network","institutionId":"erasmus-mc","specialisms":["Multiple myeloma","Transplant-eligible myeloma","Daratumumab quadruplets","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sonneveld%20P%5BAuthor%5D%20myeloma%20daratumumab%20PERSEUS"}],"papers":[{"title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma (PERSEUS)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2312054"},{"title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial","journal":"JCO","year":2012,"doi":"10.1200/JCO.2011.39.6820"}]},"route":"/people/pieter-sonneveld/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"target":[{"id":"cd38","kind":"target","name":"CD38","route":"/targets/cd38/"}],"company":[{"id":"hovon","kind":"company","name":"HOVON","route":"/companies/hovon/"}],"institution":[{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","route":"/institutions/erasmus-mc/"}],"trial":[{"id":"perseus","kind":"trial","name":"PERSEUS","route":"/trials/perseus/"}],"paper":[{"id":"paper-perseus-dara-vrd-transplant-nejm-2024","kind":"paper","name":"PERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma","route":"/key-papers/paper-perseus-dara-vrd-transplant-nejm-2024/"}]}}